Europe Antibiotics & Antimycotics Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

Europe Antibiotics & Antimycotics Market Outlook

Companies in the antibiotics and antimycotics market are making continuous efforts to develop new products or update the existing ones, and to raise funds for drug development and clinical studies. Initiatives and support from private and government organizations also drive evolution in antibiotics and antimycotics. A few of the recent developments that took place in the market in recent years are mentioned below.

• In September 2024, F2G, a UK-based biopharmaceutical company, completed a US$ 100-million financing round to conduct the late-stage development and commercialization of olorofim, a novel oral antifungal therapy for invasive aspergillosis and other invasive fungal infections.
• In June 2024, the Global Antibiotic Research & Development Partnership (GARDP) and Bugworks Research Inc (Bugworks) signed a collaborative agreement for jointly developing an innovative compound termed BWC0977. This candidate exhibits a broad-spectrum antibiotic activity against multidrug-resistant bacteria responsible for life-threatening infections.
• In June 2023, BioVersys became the first European company to receive funding for its clinical trials through the AMR Action Fund. This fund operates as the world’s second-largest foundation that aims to promote medical research; it is expected to support the launch of 2–4 antimicrobials to combat resistance in bacteria by 2030.
• In October 2022, CARB-X launched new funding rounds for critical global health needs focused on preventatives, diagnostics and therapeutics that address neonatal sepsis, gonorrhea and the most threatening antimicrobial-resistant bacterial infections. These product range includes oral therapeutics, vaccines for neonatal sepsis, and Gonorrhea products.

Therefore, the ongoing funding, research and development initiatives by companies and academic organizations are expected to create ample opportunities for the growth of the antibiotics and antimycotics market in the coming years.

Europe Antibiotics & Antimycotics Market Country Insights

Based on country, the Europe antibiotics & antimycotics market comprises Germany, France, Spain, Italy, the UK, and the Rest of Europe. Germany held the largest share in 2023.

The antibiotics and antimycotics market in Germany is driven by the rising prevalence of bacterial and fungal infections and a growing awareness of antimicrobial resistance (AMR), which results in healthcare professionals and policymakers prioritizing effective treatment options. According to Bundesministerium fur Gesundheit (BMG) 2021 report, more than 500,000 people in Germany suffer from pneumonia every year, out of which 250,000 receive treatment in hospitals, and 20,000 people die due to the disease. As per The Robert Koch Institute 2024 report, approximately 400,000 to 600,000 patients suffer a hospital-acquired infection each year, recording 10,000–20,000 associated deaths in Germany. In addition, there is an increasing focus on research and development, along with investments in biopharmaceutical companies and academic institutions dedicated to the development of new antibiotics and antifungals. The government has implemented various initiatives aimed at enhancing the sustainability of antibiotic use, including the German Antibiotic Resistance Strategy (DART 2030), which emphasizes stewardship programs to optimize prescribing practices and reduce unnecessary use of antimicrobials. Moreover, strategic developments such as collaboration among market players in the country are further expected to contribute to the growth of the antibiotics and antimycotics market in the coming years. For instance, in June 2022, Boehringer Ingelheim, Evotec, and bioMérieux launched Aurobac, a joint venture to fight Antimicrobial Resistance.

Europe Antibiotics & Antimycotics Market Report Highlights

Europe Antibiotics & Antimycotics Market Company Profiles

Some of the key players operating in the market are Pfizer Inc, Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co Inc, GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc, and Astellas Pharma Inc, among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Europe Antibiotics & Antimycotics Market Research Methodology :

The following methodology has been followed for the collection and analysis of data presented in this report:

• Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations.
• Industry trade journals and other relevant publications.
• Government documents, statistical databases, and market reports.
• News articles, press releases, and webcasts specific to companies operating in the market.

Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.

• Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research.
• Enhance the expertise and market understanding of the analysis team.
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects.

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise

Europe Antibiotics & Antimycotics Market Country and Regional Insights